This document has been produced as a collaboration between London and South East Medicines Information Service, South West Medicines Information Service and Croydon Primary Care Trust. It outlines UK published recommendations for monitoring safety parameters for a range of medicines that may be prescribed for adults in primary care and highlights areas where local consensus is required to address discrepancies or gaps. The information is presented in terms of monitoring required at baseline, during initiation, during maintenance, actions required when faced with an abnormal result, other relevant information, and BNF-listed significant drug interactions.

The drugs covered include: amiodarone, azathioprine, bendroflumethiazide, bumetanide, candesartan, captopril, carbamazapine, carbimazole, celecoxib, ciclosporin, corticosteroids, digoxin, diuretics, enalapril, eplenerone, fluvastatin, furosemide, hydroxychloroquine, hydroxycarbamide, hydroxyurea, irbesartan, ketoconazole, leflunomide, lisinopril, losartan, lithium, mercaptopurine, mesalazine, methotrexate, minocycline, NSAIDs, olanzapine, perindopril, D-penicillamine, pravastatin, phenytoin, pioglitazone, propylthiouracil, ramipril, rosiglitazone, rosuvastatin, risperidone, sibutramine, simvastatin, sodium valproate, valproate, spironolactone, statins, sulfasalazine, telmisartan, theophylline, thyroxine, vigabatrin and warfarin. A Word version of the document can be made available for local adaptation if required - please contact us if you would like a copy emailed to you.